J&J plans late-stage trial for lupus candidate after Phase 2 successnews2026-01-06T19:11:01+00:00January 6th, 2026|Endpoints News|
Bright Minds’ shares soar on positive Phase 2 seizure reduction datanews2026-01-06T16:33:16+00:00January 6th, 2026|Endpoints News|
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approvalnews2026-01-06T16:22:38+00:00January 6th, 2026|Endpoints News|
Amgen to acquire Dark Blue Therapeutics for up to $840Mnews2026-01-06T15:49:45+00:00January 6th, 2026|Endpoints News|
Roche’s patent deal with Structure; AstraZeneca reports lupus datanews2026-01-06T14:49:42+00:00January 6th, 2026|Endpoints News|
Protagonist ‘strongly leaning’ toward opting out of Takeda profit-sharing dealnews2026-01-06T14:34:45+00:00January 6th, 2026|Endpoints News|
Lilly goes back to Nimbus for an oral obesity drug in $55M dealnews2026-01-06T13:00:47+00:00January 6th, 2026|Endpoints News|
Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early datanews2026-01-06T12:30:29+00:00January 6th, 2026|Endpoints News|
Cartography does another pharma deal, this time with Pfizernews2026-01-06T12:30:19+00:00January 6th, 2026|Endpoints News|
Mediar Therapeutics gains $76M to get three fibrosis drugs to key clinical datanews2026-01-06T12:00:20+00:00January 6th, 2026|Endpoints News|
